Safety analysis population (n = 2602) | Efficacy analysis population (n = 1629) | |
Number of patients | 2602 | 1629 |
Number of patients with adverse drug reactions | 14 | 8 |
Number of cases of adverse drug reactions | 15 | 9 |
Incidence (%) of adverse drug reactions | 0.54% | 0.49% |
Types of adverse drug reactions | Incidence of serious adverse drug reactions by type number of patients (%) | |
Metabolism and nutrition disorders | 9 (0.35) | 4 (0.25) |
Inadequate glycaemic control | 1 (0.04) | 0 (0.00) |
Hypoglycaemia | 8 (0.31) | 4 (0.25) |
Nervous system disorders | 1 (0.04) | 1 (0.06) |
Hypoglycaemic seizure | 1 (0.04) | 1 (0.06) |
Hypoglycaemic unconsciousness | 1 (0.04) | 1 (0.06) |
Eye disorders | 1 (0.04) | 1 (0.06) |
Diabetic retinopathy | 1 (0.04) | 1 (0.06) |
General disorders and administration site conditions | 1 (0.04) | 1 (0.06) |
Death* | 1 (0.04) | 1 (0.06) |
Laboratory tests | 2 (0.08) | 1 (0.06) |
Blood glucose level increased | 2 (0.08) | 1 (0.06) |